Home
HelpTest Code AFOLR Folate Receptor Alpha (FOLR1), Semi-Quantitative Immunohistochemistry, Manual
Ordering Guidance
This test may be utilized for all types of ovarian cancers.
Shipping Instructions
Attach the green "Attention Pathology" address label (T498) to the outside of the transport container before putting into the courier mailer.
Necessary Information
A pathology/diagnostic report and a brief history are required.
Specimen Required
Specimen Type: Tissue
Source: Ovarian tumor
Supplies: Pathology Packaging Kit (T554)
Collection Instructions: Formalin-fixed, paraffin-embedded tissue block; or 3 unstained glass, "positively charged" slides with 4-microns formalin-fixed, paraffin-embedded tissue
Additional Information: One slide will be stained with hematoxylin and eosin and returned.
Useful For
Diagnosis of epithelial ovarian cancer that may be eligible for treatment with an anti-folate receptor 1 protein antibody
Method Name
Immunohistochemistry (IHC)
Reporting Name
FOLR1, SemiQuant IHC, ManualSpecimen Type
SpecialSpecimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Special | Ambient (preferred) | ||
| Refrigerated | |||
Reference Values
An interpretive report will be provided.
Interpretation
Folate receptor 1 protein (FOLR1) is a biomarker that, when positive (at least moderate membranous staining) in greater than or equal to 75% of tumor cells, predicts response to treatment with Elahere (mirvetuximab soravtansine) and has been approved for epithelial ovarian, fallopian tube, or primary peritoneal cancer.(1)
This result should be interpreted in the appropriate clinical context.
Clinical Reference
1. VENTANA FOLR1 (FOR-2.1) RxDx Assay. US Package Insert. Roche Diagnostics; 2022
2. Scaranti M, Cojocaru E, Banerjee S, et al. Exploiting the folate receptor alpha in oncology. Nat Rev Clin Oncol. 2020;17(6):349-359
3. Necela B, Crozier J, Andorfer C, et al. Folate receptor-alpha (FOLR1) expression and function in triple negative tumors. PLoS One. 2015;10(3):e0122209
4. Kobel M, Madore J, Ramus S, et al. Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study. Br J Cancer. 2014;111:2297-2307
Day(s) Performed
Monday through Friday
Report Available
5 to 7 daysPerforming Laboratory
Mayo Clinic Laboratories in Rochester
Test Classification
This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
88360
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| AFOLR | FOLR1, SemiQuant IHC, Manual | 105010-3 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 620732 | Interpretation | 50595-8 |
| 621015 | Participated in the Interpretation | No LOINC Needed |
| 621016 | Report electronically signed by | 19139-5 |
| 621017 | Material Received | 81178-6 |
| 621018 | Disclaimer | 62364-5 |
| 621019 | Case Number | 80398-1 |
Forms
If not ordering electronically, complete, print, and send an Immunohistochemical (IHC)/In Situ Hybridization (ISH) Stains Request (T763) with the specimen.